EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Synthetic Lethality‐Based Targets and Their Exploration in Tumour Combination Strategies

Lingya Wu iD, Yixuan Deng, Zhe Lei, Yuhong Wang, Shan Huang

Journal of Cellular and Molecular Medicine · 2025

DOI: 10.1111/jcmm.70756 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Lingya Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Neoplasms, Synthetic Lethal Mutations, Molecular Targeted Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Suzhou health youth backbone talent 'national tutorial system' training project, National Natural Science Foundation of China, Basic science (Natural science) research project in universities of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Synthetic lethality (SL) not only addresses the challenge of drug resistance associated with classical targeted therapies but also offers innovative therapeutic approaches for previously ‘undruggable’ targets, such as deletion mutations in tumour suppressor genes. Advances in technology have significantly enhanced our understanding of gene–gene interactions in cancer cells, enabling the identification of synthetic lethal targets and the development of drugs targeting these mechanisms. Following the extensive clinical application of PARP inhibitors—the first synthetic lethal targeted drugs approved for clinical use—emerging targets such as ATR, WEE1 and WRN have demonstrated promising clinical potential. This review examines the functions and molecular mechanisms underlying these targets and discusses recent advancements in the theory of synthetic lethality. Additionally, it emphasises the integration of synthetic lethal drugs with traditional cancer treatments, highlighting the clinical benefits of this combined strategy and its potential to facilitate more precise and individualised cancer treatment modalities in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsSynthetic Lethal MutationsMolecular Targeted TherapyHumansAnimalsPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic Agents

Stichwörter der Autor:innen

DNA repairPARP inhibitorscancer therapycombined strategysynthetic lethality

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.

ORCID-Profile: Lingya Wu

Förderung

  • Suzhou health youth backbone talent 'national tutorial system' training project
  • National Natural Science Foundation of China
  • Basic science (Natural science) research project in universities of Jiangsu Province
  • Suzhou "Gusu Medical Star" Young Science and Technology Talent Support Project
  • Suzhou Science and Technology Bureau basic research special youth project
  • Suzhou Basic Research Pilot Program

Zitieren

APA

Wu, L., Deng, Y., Lei, Z., Wang, Y., & Huang, S. (2025). Synthetic Lethality‐Based Targets and Their Exploration in Tumour Combination Strategies. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70756

Vancouver

Wu L, Deng Y, Lei Z, Wang Y, Huang S. Synthetic Lethality‐Based Targets and Their Exploration in Tumour Combination Strategies. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70756

BibTeX
@article{Wu2025,
  author = {Wu, Lingya and Deng, Yixuan and Lei, Zhe and Wang, Yuhong and Huang, Shan},
  title = {Synthetic Lethality‐Based Targets and Their Exploration in Tumour Combination Strategies},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2025},
  doi = {10.1111/jcmm.70756}
}
Kostenlos starten →